Anti-Rheumatic Rx
Richard Conway RichardPAConway
9 months 2 weeks ago
Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz
Antoni Chan MD (Prof) synovialjoints
9 months 2 weeks ago
Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT
Richard Conway RichardPAConway
9 months 2 weeks ago
Pasoto et al. Holding MMF for 1 week after zoster vaccine (RZV) improves response with no increase in flare @RheumNow #ACR24 Abstr#0247 https://t.co/q757bMFp7I https://t.co/rwjz3q3MaO
Jiha Lee JihaRheum
9 months 2 weeks ago
Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7
Mike Putman EBRheum
9 months 2 weeks ago
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis
Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction?
#ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW
David Liew drdavidliew
9 months 2 weeks ago
Which immunomodulators dampen recombinant zoster vaccine immunogenicity?
In this 🇧🇷 study in autoimmune dx patients, overrepresented in non-responders are:
- rituximab pts
- 'combined therapy'
strategies needed for them
but reassuring for the others!
#ACR24 ABST0248 @RheumNow https://t.co/he1ICa9WZg
David Liew drdavidliew
9 months 2 weeks ago
Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT.
A week off post-vaccine: definitely worth considering in stable disease
#ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD
David Liew drdavidliew
9 months 2 weeks ago
It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have changed over that time.
MarketScan data tell a story of fashion and fame. What will the next 20 years be like?
#ACR24 ABST0509 @jeffsparks @RheumNow https://t.co/wCcWgkHrvc
Brian Jaros, MD Dr_Brian_MD
9 months 2 weeks ago
Major update in tx for GCA beyond Toci
SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk)
No significant adverse safety signal w JAKi including MACE/malignancy
@RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N
Caoilfhionn Connolly CaoilfhionnMD
9 months 2 weeks ago
#0509
📊 RA DMARD Trends in US (2001-2021)
🧑🤝🧑 407,728 DMARD starts in 229,365 patients
📉 csDMARD use fell (79.7% → 54.7%)
‼️Methotrexate dropped 29% → 15%
📈 bDMARDs (20.3% →33.1%),tsDMARDs (0.1% → 12.2%) both ⬆️⬆️
💊Biosimilar uptake low
#ACR24 @RheumNow @jeffsparks https://t.co/JepaWj7azY
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and
Brian Jaros, MD Dr_Brian_MD
9 months 2 weeks ago
EGPA: To RTX or not to RTX?
French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy
Huge anticipation for these results, hopefully next year!
#ACR24 @RheumNow https://t.co/POelLpirrI
Eric Dein ericdeinmd
9 months 2 weeks ago
Knee OA
Krill oil - No benefit in randomized PBO control study
MTX (25 mg) for pain - modest diff in pain (numerical, not WOMAC), lost by 12 mo
STEP-9: GLP1 agonist for BMI>30 w knee OA. 60% better than PBO. Wt or other benefits?
@RheumNow
Michael Pillinger
#ACR24 year in review https://t.co/dMw4T0tWLX
Brian Jaros, MD Dr_Brian_MD
9 months 2 weeks ago
Abatacept for GPA?
Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA
Continued need for tx options in non-severe relapsing dz
@RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Poster Hall